Home » Topics » BioWorld Science

BioWorld Science
RSS

Novel beta-glucuronidase inhibitors patented by UNC Chapel Hill

Feb. 5, 2018

Amgen discovers new sodium channel blockers

Feb. 5, 2018

Tetra Bio-Pharma cleared to begin phase III trial of PPP-001 in patients with terminal cancer

Feb. 5, 2018

ReViral reports promising outcome from phase IIa challenge study of RV-521 in RSV

Feb. 5, 2018

A1M Pharma seeks Swedish clearance to begin phase I study of ROSgard

Feb. 5, 2018

NEOLAP trial interim results presented for patients with LAPC

Feb. 5, 2018

Phase III AEGIS-CKD study of Feraccru does not meet primary endpoint

Feb. 5, 2018

Shanghai Synergy initiates phase I/II study in China with hypidone in major depressive disorder

Feb. 5, 2018

Astellas Pharma, Pfizer support research into role of AR in breast cancer

Feb. 5, 2018

Novo Nordisk updates events of fourth quarter 2017

Feb. 5, 2018

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 14, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...